Draft guidance would allow alternative evidence standards to accelerate approval of personalized treatments targeting conditions affecting fewer than 200,000 Americans.
By yourNEWS Media Newsroom
U.S. regulators on Feb. 23 released draft guidance outlining a new regulatory pathway intended to accelerate the development and approval of personalized therapies targeting rare genetic disorders, according to a report by The Epoch Times.
The Food and Drug Administration said the proposal would make it easier to secure approval for genome editing and ribonucleic acid-based treatments designed for ultra-rare conditions, defined as diseases affecting fewer than 200,000 people in the United States.
FDA officials stated that because of the small number of patients impacted by such disorders, conducting large-scale randomized, controlled clinical trials—the standard method for demonstrating drug effectiveness—may not be feasible. Under the proposed framework, alternative forms of evidence, including biomarker responses or observable clinical outcomes, could be sufficient to support approval.
“This guidance is a critical step the FDA is taking to tailor our regulatory approach to patients with ultra-rare conditions,” FDA Commissioner Dr. Marty Makary said in a statement. “It is our priority to remove barriers and exercise regulatory flexibility to encourage scientific advances and deliver more cures and meaningful treatments for patients suffering from rare diseases.”
Health Secretary Robert F. Kennedy Jr. described the proposal as an effort to reduce regulatory obstacles. He pointed to the case of a baby identified as KJ, who received a custom gene-editing therapy at approximately seven and eight months of age. Researchers reported that the treatment appeared to cure the child’s genetic disorder.
Kennedy said the baby’s recovery was “a medical miracle” and that after learning of the case, he directed the FDA to expand access to similar customized therapies. “Every child facing rare genetic diseases deserves the kind of treatment that baby KJ got,” he said.
Dr. Kiran Musunuru, director of the Penn Cardiovascular Institute’s Genetic and Epigenetic Origins of Disease Program and one of the physicians involved in developing the therapy, said during an event in Washington that the case demonstrated broader potential. “We realized we could do this over and over again,” Musunuru said.
The proposed pathway was first previewed in late 2025 in an article authored by Makary and Dr. Vinay Prasad, head of the FDA’s Center for Biologics Evaluation and Research, in the New England Journal of Medicine. The officials wrote at the time that the agency would consider approving bespoke therapies supported by data from only several patients, provided the pharmacologic effect aligned with biological plausibility and observed clinical outcomes.
“An appropriately designed study with a small sample size can support licensure of a product for which pharmacologic effect is aligned with biologic plausibility and congruent with observed clinical outcomes,” they wrote. “That philosophy, in essence, embodies the plausible mechanism pathway.”
The Feb. 23 draft guidance states that the initiative was jointly developed by the Center for Biologics Evaluation and Research and the FDA’s Center for Drug Evaluation and Research, currently led on an acting basis by Dr. Tracy Beth Hoeg.
Hoeg said during Monday’s event that officials anticipate the proposed framework, if finalized, could significantly shorten development timelines for therapies addressing ultra-rare conditions. She expressed hope that approvals could be “sped up dramatically” under the new approach.
The draft guidance will be published in the Federal Register at Regulations.gov. Upon publication, a 60-day public comment period will begin before the agency considers finalizing the policy.
Original article
Comments